CEGEDIM SA (CGM.PA) Stock Fundamental Analysis
EPA:CGM - Euronext Paris - Matif - FR0000053506 - Common Stock - Currency: EUR
Taking everything into account, CGM scores 3 out of 10 in our fundamental rating. CGM was compared to 12 industry peers in the Health Care Technology industry. CGM has a bad profitability rating. Also its financial health evaluation is rather negative. CGM has a valuation in line with the averages, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year CGM was profitable.
CGM had a positive operating cash flow in the past year.
CGM had positive earnings in 4 of the past 5 years.
CGM had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 0.20%, CGM is in line with its industry, outperforming 41.67% of the companies in the same industry.
The Return On Equity of CGM (0.72%) is comparable to the rest of the industry.
The Return On Invested Capital of CGM (2.46%) is comparable to the rest of the industry.
Measured over the past 3 years, the Average Return On Invested Capital for CGM is below the industry average of 7.83%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.2% | ||
| ROE | 0.72% | ||
| ROIC | 2.46% |
ROA(3y)1.34%
ROA(5y)1.11%
ROE(3y)4.47%
ROE(5y)3.99%
ROIC(3y)3.09%
ROIC(5y)4.03%
1.3 Margins
CGM has a Profit Margin of 0.32%. This is comparable to the rest of the industry: CGM outperforms 41.67% of its industry peers.
CGM has a Operating Margin (3.16%) which is in line with its industry peers.
In the last couple of years the Operating Margin of CGM has declined.
With a Gross Margin value of 18.91%, CGM is not doing good in the industry: 83.33% of the companies in the same industry are doing better.
CGM's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.16% | ||
| PM (TTM) | 0.32% | ||
| GM | 18.91% |
OM growth 3Y-24.35%
OM growth 5Y-12.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.26%
GM growth 5Y0.61%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so CGM is destroying value.
Compared to 1 year ago, CGM has less shares outstanding
The number of shares outstanding for CGM has been reduced compared to 5 years ago.
Compared to 1 year ago, CGM has an improved debt to assets ratio.
2.2 Solvency
CGM has an Altman-Z score of 1.21. This is a bad value and indicates that CGM is not financially healthy and even has some risk of bankruptcy.
CGM has a Altman-Z score (1.21) which is comparable to the rest of the industry.
CGM has a debt to FCF ratio of 26.87. This is a negative value and a sign of low solvency as CGM would need 26.87 years to pay back of all of its debts.
CGM has a Debt to FCF ratio (26.87) which is in line with its industry peers.
CGM has a Debt/Equity ratio of 0.95. This is a neutral value indicating CGM is somewhat dependend on debt financing.
CGM has a Debt to Equity ratio of 0.95. This is in the lower half of the industry: CGM underperforms 66.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | 26.87 | ||
| Altman-Z | 1.21 |
ROIC/WACC0.64
WACC3.84%
2.3 Liquidity
A Current Ratio of 0.88 indicates that CGM may have some problems paying its short term obligations.
CGM has a worse Current ratio (0.88) than 75.00% of its industry peers.
A Quick Ratio of 0.86 indicates that CGM may have some problems paying its short term obligations.
CGM has a worse Quick ratio (0.86) than 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.86 |
3. Growth
3.1 Past
The earnings per share for CGM have decreased strongly by -79.22% in the last year.
The Revenue has been growing slightly by 7.70% in the past year.
CGM shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.66% yearly.
EPS 1Y (TTM)-79.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%107.15%
Revenue 1Y (TTM)7.7%
Revenue growth 3Y7.42%
Revenue growth 5Y5.66%
Sales Q2Q%5.97%
3.2 Future
Based on estimates for the next years, CGM will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.53% on average per year.
The Revenue is expected to grow by 4.74% on average over the next years.
EPS Next Y3.67%
EPS Next 2Y20.21%
EPS Next 3Y18.53%
EPS Next 5YN/A
Revenue Next Year5.16%
Revenue Next 2Y5.05%
Revenue Next 3Y4.74%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 88.00, CGM can be considered very expensive at the moment.
CGM's Price/Earnings ratio is in line with the industry average.
CGM is valuated expensively when we compare the Price/Earnings ratio to 29.07, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 8.30 indicates a reasonable valuation of CGM.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CGM indicates a rather cheap valuation: CGM is cheaper than 100.00% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.05. CGM is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 88 | ||
| Fwd PE | 8.3 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CGM is valued cheaply inside the industry as 91.67% of the companies are valued more expensively.
83.33% of the companies in the same industry are more expensive than CGM, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.7 | ||
| EV/EBITDA | 4.58 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
CGM's earnings are expected to grow with 18.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)23.98
PEG (5Y)N/A
EPS Next 2Y20.21%
EPS Next 3Y18.53%
5. Dividend
5.1 Amount
No dividends for CGM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:CGM (3/26/2025, 5:04:05 PM)
13.2
+0.2 (+1.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners17.48%
Inst Owner ChangeN/A
Ins Owners54.22%
Ins Owner ChangeN/A
Market Cap186.12M
Analysts48.89
Price Target15.58 (18.03%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.68%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-7.76%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 88 | ||
| Fwd PE | 8.3 | ||
| P/S | 0.29 | ||
| P/FCF | 14.7 | ||
| P/OCF | 2.01 | ||
| P/B | 0.67 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.58 |
EPS(TTM)0.15
EY1.14%
EPS(NY)1.59
Fwd EY12.05%
FCF(TTM)0.9
FCFY6.8%
OCF(TTM)6.57
OCFY49.78%
SpS44.96
BVpS19.76
TBVpS-11.62
PEG (NY)23.98
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.2% | ||
| ROE | 0.72% | ||
| ROCE | 3.34% | ||
| ROIC | 2.46% | ||
| ROICexc | 2.61% | ||
| ROICexgc | 12.16% | ||
| OM | 3.16% | ||
| PM (TTM) | 0.32% | ||
| GM | 18.91% | ||
| FCFM | 2% |
ROA(3y)1.34%
ROA(5y)1.11%
ROE(3y)4.47%
ROE(5y)3.99%
ROIC(3y)3.09%
ROIC(5y)4.03%
ROICexc(3y)3.3%
ROICexc(5y)4.28%
ROICexgc(3y)11.58%
ROICexgc(5y)15.94%
ROCE(3y)4.21%
ROCE(5y)5.49%
ROICexcg growth 3Y-24.58%
ROICexcg growth 5Y-49.29%
ROICexc growth 3Y-22.69%
ROICexc growth 5Y-16.24%
OM growth 3Y-24.35%
OM growth 5Y-12.47%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.26%
GM growth 5Y0.61%
F-Score4
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | 26.87 | ||
| Debt/EBITDA | 2.48 | ||
| Cap/Depr | 92.41% | ||
| Cap/Sales | 12.62% | ||
| Interest Coverage | 3.39 | ||
| Cash Conversion | 86.93% | ||
| Profit Quality | 628.08% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.86 | ||
| Altman-Z | 1.21 |
F-Score4
WACC3.84%
ROIC/WACC0.64
Cap/Depr(3y)94%
Cap/Depr(5y)98.87%
Cap/Sales(3y)12.77%
Cap/Sales(5y)13.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-79.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%107.15%
EPS Next Y3.67%
EPS Next 2Y20.21%
EPS Next 3Y18.53%
EPS Next 5YN/A
Revenue 1Y (TTM)7.7%
Revenue growth 3Y7.42%
Revenue growth 5Y5.66%
Sales Q2Q%5.97%
Revenue Next Year5.16%
Revenue Next 2Y5.05%
Revenue Next 3Y4.74%
Revenue Next 5YN/A
EBIT growth 1Y-28.71%
EBIT growth 3Y-18.74%
EBIT growth 5Y-7.51%
EBIT Next Year229.85%
EBIT Next 3Y55.74%
EBIT Next 5YN/A
FCF growth 1Y150.16%
FCF growth 3Y-14.47%
FCF growth 5Y-19.09%
OCF growth 1Y118.9%
OCF growth 3Y-3.91%
OCF growth 5Y-4.55%